the Effect of Adding Dexmedetumidine to Rupivacaine and Markain on the Pain and Shivering of patients
Phase 2
Recruiting
- Conditions
- Pain and chills in lower limb orthopedic patients.G89.18Other acute postprocedural pain
- Registration Number
- IRCT20130926014779N6
- Lead Sponsor
- Jahrom University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Having hemodynamic stability
ASA (Class 1 and 2 were considered as inclusion criteria)
Exclusion Criteria
History of cardiovascular disease
Shortness of breath
Diabetes
Kidney or liver disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The pain. Timepoint: Before the spinal, after the spinal and during the change of position of the patient and then every 15 minutes to the first hour and also during the entry into recovery and when leaving the recovery and finally three and six hours after the operation. Method of measurement: pain assessment ruler.;Shivering. Timepoint: Before the spinal, after the spinal and during the change of position of the patient and then every 15 minutes to the first hour and also during the entry into recovery and when leaving the recovery and finally three and six hours after the operation. Method of measurement: Shivering scale.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Dexmedetumidine's analgesic and antishivering effects when combined with Rupivacaine and Markain in lower limb orthopedic surgery?
How does the efficacy of Dexmedetumidine-adjuvanted Rupivacaine/Markain compare to standard-of-care local anesthetics for postprocedural pain (G89.18) in orthopedic patients?
Which biomarkers correlate with reduced postoperative shivering and pain intensity in IRCT20130926014779N6's phase II study of alpha-2 adrenergic agonist combinations?
What adverse event profiles are associated with Dexmedetumidine-Rupivacaine/Markain combinations versus traditional opioid-based analgesia in acute postprocedural pain management?
How do Dexmedetumidine's pharmacodynamic interactions with amide-type local anesthetics (Rupivacaine/Markain) influence therapeutic outcomes compared to other alpha-2 agonist adjuvants in orthopedic analgesia?